AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11751768 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin-resistant strains
Number of subjects: 2586
Study 11751768 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with macrolide consumption
Number of subjects: 2586
Study 10392220 — intervention group
Group type: EXPERIMENTAL
Intervention: Earplugs worn during exposure to noise
Number of subjects: 6
Study 10392220 — intervention group
Group type: COMPARATOR
Intervention: No earplugs (noise exposure)
Number of subjects: 6
Study 8873662 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger artery pressure (with Finapres)
Number of subjects: 57
Study 8873662 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstructed finger pressure after filtering
Number of subjects: 57
Study 1998226 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthesia
Number of subjects: 91
Study 1998226 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 91
Study 6522132 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 24
Study 6522132 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 24
Study 6522132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30865149 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 dosing protocols of motor learning-based therapy, identical number of 2-hour sessions over different total calendar weeks
Number of subjects: 75
Study 30064464 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory ergonomics intervention conducted over 4 months with three workshops to identify and reduce risk factors for MSP.
Number of subjects: 0
Study 30064464 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory ergonomics intervention
Number of subjects: 0
Study 30064464 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study 26673246 — intervention group
Group type: EXPERIMENTAL
Intervention: p-synephrine (3 mg·kg(‐1))
Number of subjects: 13
Study 26673246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 26529175 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated humidified high flow nasal cannulae (HHHFNC)
Number of subjects: 28
Study 26529175 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 28
Study 21952795 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal Welding Technique (TWT)
Number of subjects: 305
Study 21952795 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar Cautery Dissection (BCD)
Number of subjects: 305
Study 21952795 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic Dissection (CD)
Number of subjects: 305
Study 21952795 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 305
Study 20368505 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 36
Study 20368505 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 36
Study 18565733 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-Expression Training Tool (METT; n=26)
Number of subjects: 40
Study 18565733 — intervention group
Group type: COMPARATOR
Intervention: Repeated Exposure (RE; n=14)
Number of subjects: 40
Study 16354341 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency volumetric tissue reduction of the palate (BRVTR)
Number of subjects: 150
Study 16354341 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted uvulopalatoplasty (LAUP)
Number of subjects: 150
Study 12735429 — intervention group
Group type: EXPERIMENTAL
Intervention: Bruxism self-aware group (14 subjects)
Number of subjects: 30
Study 12735429 — intervention group
Group type: COMPARATOR
Intervention: Bruxism unaware group (16 subjects)
Number of subjects: 30
Study 10449550 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose bromocriptine
Number of subjects: 149
Study 10449550 — intervention group
Group type: COMPARATOR
Intervention: Low dose levodopa‐carbidopa
Number of subjects: 149
Study 10449550 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patients
Number of subjects: 149
Study 9196546 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine bromide (30 mg)
Number of subjects: 8
Study 9196546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1753613 — intervention group
Group type: EXPERIMENTAL
Intervention: Finoptin
Number of subjects: 70
Study 1753613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 6340404 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous transcutaneous PO2 measurements supplemented by blood-gas measurements only when judged necessary
Number of subjects: 20
Study 6340404 — intervention group
Group type: COMPARATOR
Intervention: Repeated blood-gas determinations according to the usual practice
Number of subjects: 20
Study 30923094 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib-dexamethasone induction treatment followed by high-dose melphalan and autologous stem cell transplantation (SCT)
Number of subjects: 50
Study 30923094 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib-dexamethasone induction treatment
Number of subjects: 50
Study 29978932 — intervention group
Group type: EXPERIMENTAL
Intervention: High rate cut-off VT zone ≥200 bpm (Arm B)
Number of subjects: 1391
Study 29978932 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 seconds delay in VT zone 170-199 bpm (Arm C)
Number of subjects: 1391
Study 29978932 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed VT therapy (Arm C)
Number of subjects: 1391
Study 27769284 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine
Number of subjects: 0
Study 27769284 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 25151520 — intervention group
Group type: EXPERIMENTAL
Intervention: Group attention during exposure to scary advertisements
Number of subjects: 0
Study 25151520 — intervention group
Group type: EXPERIMENTAL
Intervention: Group attention during exposure to negative images
Number of subjects: 0
Study 25151520 — intervention group
Group type: EXPERIMENTAL
Intervention: Group attention during exposure to positive images
Number of subjects: 0
Study 25151520 — intervention group
Group type: EXPERIMENTAL
Intervention: Group attention during a video depicting homelessness
Number of subjects: 0
Study 25151520 — intervention group
Group type: EXPERIMENTAL
Intervention: Group attention during sad videos
Number of subjects: 0
Study 25151520 — intervention group
Group type: EXPERIMENTAL
Intervention: Group attention during amusing videos
Number of subjects: 0
Study 21667200 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 149
Study 19114229 — intervention group
Group type: EXPERIMENTAL
Intervention: Haishengsu (2.4mg in 250ml normal saline, iv, for 15 days)
Number of subjects: 83
Study 19114229 — intervention group
Group type: COMPARATOR
Intervention: Placebo (250ml normal saline, iv)
Number of subjects: 83
Study 17173959 — intervention group
Group type: EXPERIMENTAL
Intervention: Colposcopy plus Optical Detection System (ODS)
Number of subjects: 2186
Study 17173959 — intervention group
Group type: COMPARATOR
Intervention: Colposcopy only
Number of subjects: 2186
Study 17185116 — intervention group
Group type: COMPARATOR
Intervention: Active control noninferiority trials
Number of subjects: 0
Study 17185116 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 14739855 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment (n=9) at a continuous rate of >=1.5 microU/kg/min to maintain euglycemia (serum glucose 100‐140 microg/dL)
Number of subjects: 18
Study 14739855 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment (n=9)
Number of subjects: 18
Study 14739855 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group, n=9)
Number of subjects: 18
Study 11165310 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg)
Number of subjects: 16
Study 11165310 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg)
Number of subjects: 16
Study 11165310 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam (30 mg)
Number of subjects: 16
Study 11165310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9069080 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy laser application
Number of subjects: 18
Study 9069080 — intervention group
Group type: COMPARATOR
Intervention: Denture removal
Number of subjects: 18
Study 9069080 — intervention group
Group type: COMPARATOR
Intervention: Relined dentures with temporary tissue treatment
Number of subjects: 18
Study 8370425 — intervention group
Group type: EXPERIMENTAL
Intervention: MOCCA (methylprednisolone, vincristine, lomustine, cyclophosphamide, melphalan)
Number of subjects: 138
Study 8370425 — intervention group
Group type: COMPARATOR
Intervention: COLA (vincristine, lomustine, cyclophosphamide, melphalan)
Number of subjects: 138
Study 3539162 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 533
Study 3539162 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 533
Study 30361956 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroperitoneal laparoscopic pyelolithotomy (RLP)
Number of subjects: 105
Study 30361956 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous nephrolithotomy (PCNL)
Number of subjects: 105
Study 30361956 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RLP and PCNL
Number of subjects: 105
Study 27634921 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity stepping training
Number of subjects: 0
Study 27634921 — intervention group
Group type: COMPARATOR
Intervention: Conventional lower-intensity interventions
Number of subjects: 0
Study 25873729 — intervention group
Group type: COMPARATOR
Intervention: Low-dose unfractionated heparin (50 U/kg)
Number of subjects: 2026
Study 25873729 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose unfractionated heparin (85 U/kg or 60 U/kg with glycoprotein IIb/IIIa inhibitors, with ACT guidance)
Number of subjects: 2026
Study 25873729 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT≤300 s (in patients not receiving planned glycoprotein IIb/IIIa inhibitors)
Number of subjects: 2026
Study 25873729 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT
Number of subjects: 2026
Study 23703418 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography to determine the relative relationship of the ulnar artery and median nerve to the PL tendon
Number of subjects: 30
Study 23703418 — intervention group
Group type: COMPARATOR
Intervention: Blind local steroid injection
Number of subjects: 30
Study 21242389 — intervention group
Group type: EXPERIMENTAL
Intervention: Photographic sun damage assessment scale graded by dermatologists
Number of subjects: 96
Study 21242389 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded rating by 5 community dermatologists using the dermatologic assessment scoring scale
Number of subjects: 96
Study 19482767 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized 2% lidocaine at 4 mg/kg
Number of subjects: 36
Study 19482767 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 36
Study 16956331 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Burch colposuspension (LBC)
Number of subjects: 200
Study 16956331 — intervention group
Group type: COMPARATOR
Intervention: Open Burch colposuspension (OBC)
Number of subjects: 200
Study 15365964 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg/dialysis iron-sucrose for Group A (iron deficient)
Number of subjects: 14
Study 15365964 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg/dialysis iron-sucrose for Group B (iron-replete)
Number of subjects: 14
Study 15365964 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg/dialysis iron-sucrose for Group A (after initial treatment)
Number of subjects: 14
Study 15365964 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg/dialysis iron-sucrose for Group B (maintenance)
Number of subjects: 14
Study 15365964 — intervention group
Group type: COMPARATOR
Intervention: No treatment for Group C (possible iron-overloaded)
Number of subjects: 14
Study 11352248 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg subcutaneously twice weekly) added to standard therapies for WG
Number of subjects: 20
Study 11352248 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg subcutaneously twice weekly)
Number of subjects: 20
Study 9869995 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 uF three-electrode defibrillation system
Number of subjects: 26
Study 9869995 — intervention group
Group type: COMPARATOR
Intervention: 125 uF two-electrode defibrillation system
Number of subjects: 26
Study 11271220 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandimmun Neoral
Number of subjects: 552
Study 11271220 — intervention group
Group type: COMPARATOR
Intervention: Sandimmun
Number of subjects: 552
Study 2498954 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.1 g/kg per dose)
Number of subjects: 12
Study 2498954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30676406 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative fluoroscopy
Number of subjects: 133
Study 28052266 — intervention group
Group type: EXPERIMENTAL
Intervention: mfERG normative database
Number of subjects: 78
Study 25596138 — intervention group
Group type: EXPERIMENTAL
Intervention: BUD/FM BAI 2 × 160/4.5 μg bid
Number of subjects: 214
Study 25596138 — intervention group
Group type: EXPERIMENTAL
Intervention: BUD/FM pMDI 2 × 160/4.5 μg bid
Number of subjects: 214
Study 25596138 — intervention group
Group type: COMPARATOR
Intervention: BUD pMDI 2 × 160 μg bid
Number of subjects: 214
Study 24107857 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based active play intervention (6-week active play programme)
Number of subjects: 0
Study 24107857 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (usual practice)
Number of subjects: 0
Study 21726291 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid tablet
Number of subjects: 11
Study 21726291 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum arabic lozenge
Number of subjects: 11
Study 21726291 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral water
Number of subjects: 11
Study 21726291 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk
Number of subjects: 11
Study 21726291 — intervention group
Group type: COMPARATOR
Intervention: Tap water
Number of subjects: 11
Study 21726291 — intervention group
Group type: COMPARATOR
Intervention: No product use
Number of subjects: 11
Study 19110988 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper endoscopy with biopsies
Number of subjects: 52
Study 16330117 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg of rofecoxib (n=21)
Number of subjects: 43
Study 16330117 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=22)
Number of subjects: 43
Study 15053241 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IL-6 in stroke patients
Number of subjects: 39
Study 15053241 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol levels in stroke patients
Number of subjects: 39
Study 15053241 — intervention group
Group type: EXPERIMENTAL
Intervention: Diurnal variations of cortisol
Number of subjects: 39
Study 15053241 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IL-6 levels in stroke patients
Number of subjects: 39
Study 15053241 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of IL-6 and cortisol in stroke patients
Number of subjects: 39
Study 15053241 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning serum IL-6 level
Number of subjects: 39
Study 11424113 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir for 5 days
Number of subjects: 16
Study 11424113 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 5 days
Number of subjects: 16
Study 11424113 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (oseltamivir and placebo)
Number of subjects: 16
Study 9262212 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual visual feedback rotation (10 degree-step increments up to 90 degrees)
Number of subjects: 0
Study 9262212 — intervention group
Group type: COMPARATOR
Intervention: Constant visual feedback rotation (90 degrees throughout the experiment)
Number of subjects: 0
Study 8316982 — intervention group
Group type: EXPERIMENTAL
Intervention: External hip protectors
Number of subjects: 447
Study 8316982 — intervention group
Group type: COMPARATOR
Intervention: No external hip protectors (control)
Number of subjects: 447
Study 3551507 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg (two 10 mg capsules, t.i.d.)
Number of subjects: 28
Study 3551507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 3551507 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg
Number of subjects: 28
Study 29728364 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational diabetes mellitus (GDM) without subsequent diabetes
Number of subjects: 1226
Study 29728364 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational diabetes mellitus (GDM) with subsequent diabetes
Number of subjects: 1226
Study 29728364 — intervention group
Group type: COMPARATOR
Intervention: Women without GDM or subsequent diabetes (Control group)
Number of subjects: 1226
Study 28073840 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonidegib 200 mg daily
Number of subjects: 230
Study 28073840 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonidegib 800 mg daily
Number of subjects: 230
Study 25963351 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation under isoflurane anesthesia
Number of subjects: 20
Study 25963351 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation under propofol anesthesia
Number of subjects: 20
Study 25963351 — intervention group
Group type: COMPARATOR
Intervention: Moderate hyperventilation under propofol anesthesia
Number of subjects: 20
Study 25963351 — intervention group
Group type: COMPARATOR
Intervention: Normoventilation under propofol anesthesia
Number of subjects: 20
Study 22544839 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety Sensitivity (AS)
Number of subjects: 242
Study 22544839 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic attack history
Number of subjects: 242
Study 21666941 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam + fentanyl sedation (Group S)
Number of subjects: 30
Study 21666941 — intervention group
Group type: COMPARATOR
Intervention: general anesthesia (Group G)
Number of subjects: 30
Study 18288935 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 189
Study 18288935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study 16772796 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonate-type compounds (calcitonin, clodronate, alendronate)
Number of subjects: 0
Study 16772796 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous phentolamine
Number of subjects: 0
Study 16772796 — intervention group
Group type: COMPARATOR
Intervention: Steroids
Number of subjects: 0
Study 16772796 — intervention group
Group type: COMPARATOR
Intervention: Thalidomide and TNF-alpha blockers
Number of subjects: 0
Study 16772796 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin, tricyclic antidepressants, opioids
Number of subjects: 0
Study 16772796 — intervention group
Group type: COMPARATOR
Intervention: Intensive physical therapy, nerve blocks, sympathectomy, intraspinally administered drugs, neuromodulatory therapies (spinal cord stimulation)
Number of subjects: 0
Study 12789896 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11140235 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamphetamine
Number of subjects: 4
Study 11140235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 9160820 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable diet (25% +/- 3% fat calories)
Number of subjects: 10
Study 9160820 — intervention group
Group type: COMPARATOR
Intervention: Control diet (29% +/- 2% fat calories)
Number of subjects: 10
Study 7525652 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HDMTX) 1 g/m2 per 24 h i.v., n = 47
Number of subjects: 101
Study 7525652 — intervention group
Group type: COMPARATOR
Intervention: Low-dose methotrexate (LDMTX) 30 mg/m2 by mouth every 6 h x 6, n = 54
Number of subjects: 101
Study 7525652 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (HDMTX and LDMTX)
Number of subjects: 101
Study 3597106 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention agencies
Number of subjects: 100
Study 3597106 — intervention group
Group type: COMPARATOR
Intervention: Comparison agencies
Number of subjects: 100
Study 29843781 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin
Number of subjects: 102
Study 29843781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 27863314 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation (CR)
Number of subjects: 112
Study 27863314 — intervention group
Group type: COMPARATOR
Intervention: Computer skills control intervention
Number of subjects: 112
Study 26333801 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based therapy (MT)
Number of subjects: 60
Study 26333801 — intervention group
Group type: COMPARATOR
Intervention: Social support (SS)
Number of subjects: 60
Study 24520757 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound of calcaneus
Number of subjects: 100
Study 24520757 — intervention group
Group type: COMPARATOR
Intervention: DXA (dual-energy X-ray absorptiometry)
Number of subjects: 100
Study 21632497 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive BP control (systolic BP ≤ 130 mm Hg)
Number of subjects: 37736
Study 21632497 — intervention group
Group type: COMPARATOR
Intervention: Standard BP control (systolic BP ≤ 140 mm Hg)
Number of subjects: 37736
Study 21632497 — intervention group
Group type: EXPERIMENTAL
Intervention: More intensive BP control (systolic BP < 130 mm Hg)
Number of subjects: 37736
Study 21632497 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic BP < 130 mm Hg
Number of subjects: 37736
Study 18326958 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan 5/160 mg
Number of subjects: 894
Study 18326958 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan 10/160 mg
Number of subjects: 894